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Abstract
Background: Androgen-independent prostate adenocarcinomas are responsible for about 6% of
overall cancer deaths in men.
Methods: We used DNA microarrays to identify genes related to the transition between
androgen-dependent and androgen-independent stages in the LuCaP 23.1 xenograft model of
prostate adenocarcinoma. The expression of the proteins encoded by these genes was then
assessed by immunohistochemistry on tissue microarrays (TMA) including human prostate
carcinoma samples issued from 85 patients who had undergone radical prostatectomy.
Results: FGFR1, TACC1 and WT1 gene expression levels were associated with the androgen-
independent stage in xenografts and human prostate carcinoma samples. MART1 protein
expression was correlated with pT2 tumor stages.
Conclusion: Our results suggest that each of these four genes may play a role, or at least reflect
a stage of prostate carcinoma growth/development/progression.
Background
Prostate adenocarcinoma is the most common cancer in
men in western countries, and is responsible for about 6%
of overall cancer deaths [1]. Localized prostate adenocar-
cinoma is usually treated by either surgery or radiother-
apy. In the early stages, tumor growth is dependent on
androgen stimulus and androgen ablation may be used as
a complementary therapy. The tumor then progresses to
an androgen-independent stage against which hormone
therapy has no effect. Currently, there is no effective ther-
apy against androgen-independent prostate cancer.
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The molecular biology of prostate cancer is not well
understood. Several previous reports have proposed can-
didate molecules linked to hereditary prostate cancer
[3,4]. GSTP1, PTEN, TP53, and androgen receptor (AR)
are mutated or deregulated in sporadic prostate cancer [5]
and may become targets for innovative therapies.
Recently, DNA microarrays experiments have identified
other potential prognostic markers and/or targets, such as
Hepsin/TMPRSS1, PSMA, and MMR genes [6,7] and gene
fusions [8]. Overall, little is known about the progression
from androgen-dependent to androgen-independent
stages [2].
The LuCaP 23.1 human prostate carcinoma xenograft
model [9] mimics the different stages of tumor growth
and may be an adequate system to identify the molecular
events associated with cancer progression [10]. Like for
human samples, DNA microarray analyses of xenograft
model systems have led to the discovery of several genes
associated with cancer progression. However, although
xenograft model systems are invaluable for gene discovery
studies, as well as for experimental therapeutics, there is
concern that growth of human cancer cells in an immuno-
compromised mouse host may not always be representa-
tive of progression of cancer in patients [11]. Combined
gene and protein expression profilings – e.g. DNA micro-
arrays and tissue microarrays (TMA) [12] – may allow eas-
ier or quicker validation of results provided by xenograft
studies.
In the present work, we used DNA microarrays to identify
candidate genes correlated with progression to androgen-
resistant stage in the LuCaP 23.1 xenograft model. The
expression of candidate genes with available and well-per-
forming antibody was then assessed by immunohisto-
chemistry (IHC) on TMA including human prostate
carcinoma samples from 85 patients who had undergone
radical prostatectomy.
Methods
Patient samples
Formalin-fixed, paraffin-embedded samples were
obtained from 85 distinct prostatectomy specimens
(Table 1). They included 80 tumor samples issued from
prostatectomy specimens of carcinoma ranging from
pT2aN0M0 to pT3bN0M0 stages (2002 pTNM classifica-
tion of UICC), 5 carcinoma samples from carcinomas
with distant metastases (N1 or M1 stages) classified as
"hormone refractory" (HR), 11 benign prostate tissue
samples, studied as control samples (these samples were
obtained from benign tissue areas in 11 of the 85 above-
mentioned prostatectomy specimens). This study was
approved and executed in compliance with our institu-
tional review board.
LuCaP 23.1 xenograft model
Fresh frozen tumor samples were obtained from four dif-
ferent mice bearing the LuCaP 23.1 xenograft [9]. Each
mouse was sampled three times, reflecting three distinct
stages of tumor progression: primary tumor (day 1 post-
transplantation), hormone sensitive (HS) tumor (day 7
post-transplantation), and hormone refractory (HR)
tumor (day 114 post- transplantation).
Table 1: Patients and tumor characteristics.
Characteristics All patients (n = 85)
Median age (years) 62
TNM classification:
pT0 11
pT1 0
pT2a 10
pT2b 30
pT3a 28
pT3b 17
T3N1M1b 3
T3N1M1c 2
Gleason grading:
5 4
6 8
7 53
8 15
9 5
Median follow-up (months) 60
Metastatic relapse (n) 4
Death (n) 3
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RNA extraction
Total RNA was extracted from tissue samples by lysis in
guanidium isothiocyanate and centrifugation over a
cesium chloride cushion following standard protocols
[13]. RNA quality was assessed by denaturing formalde-
hyde agarose gel electrophoresis and reverse-transcribed
PCR (RT-PCR) amplification of the β2-microglobulin
transcript.
DNA microarrays preparation and analysis
We used DNA microarrays to compare the mRNA expres-
sion profiles of ~1.000 selected genes between primary,
HS, and HR tumors in the LuCaP 23.1 xenograft model of
prostate carcinoma. RNA extracts were pooled according
to the three distinct stages of tumor progression in the
LuCaP 23.1 model (4 samples/tumor stage). DNA micro-
array hybridizations were done as previously described
[14,15] on home-made nylon DNA microarrays (TAGC,
Marseille-Luminy, France), which contained spotted PCR
products from 945 human cDNA clones. Most genes were
selected for a proven or putative implication in cancer
and/or in immune reactions. Microarrays were hybridized
with 33P-labeled probes made from 5 μg of total RNA.
Probe preparations, hybridizations, and washes were
done as previously described [14]. Briefly, 5 μg of total
RNA were retrotranscribed in the presence of [-33P] dCTP
(Amersham Biosciences). Hybridizations were done dur-
ing 48 hours at 68°C in a final volume of 10 mL of buffer.
After washes, arrays were exposed for 24 hours to phos-
phorimaging plates. Detection scanning was done with a
FUJI BAS 5000 machine at 25-μm resolution (Raytest,
Paris, France) and quantification of hybridization signals
with the ArrayGauge software (Fuji Ltd, Tokyo, Japan). All
hybridization images were inspected for artifacts, and
aberrant spots or microarray regions were excluded from
analyses. Data were analyzed as previously reported [18].
Hierarchical clustering was applied to the tissue samples
and the genes using the Cluster program developed by
Eisen [16].
All data are compliant with Minimum Information about
Microarray Experiment (MIAME) guidelines and have
been submitted to Gene Expression Omnibus (GEO)
database [GEO: GSE6284].
Tissue microarray (TMA) construction
The TMA included 96 formalin-fixed, paraffin-embedded
human prostate tissue samples. TMA was prepared as
described [17] with slight modifications. For each tumor,
one representative tumor area was carefully selected from
a hematoxylin- and eosin-stained section of a donor
block. Core cylinders with a diameter of 1,2 mm each
were punched from each of these areas and deposited into
a recipient paraffin block using a specific arraying device
(Beecher Instruments, Silver Spring, MD). Five-μm sec-
tions of the resulting microarray block were made and
used for IHC analysis after transfer to glass slides.
Immunohistochemical analysis
The antibodies used are listed in Table 2. PSA was used as
a positive control of prostate tissue. Immunohistochemis-
try (IHC) was performed by using standard protocols.
Briefly, IHC was performed on 5-μm sections of formalin-
embedded tissue specimens. They were deparaffinized in
histolemon (Carlo Erba Reagenti, Rodano, Italy) and
rehydrated in graded alcohol. Antigen enhancement was
done by incubating the sections in target retrieval solution
(DAKO, Copenhagen, Denmark) as recommended. Slides
were then transferred to a DAKO autostainer. Staining was
done at room temperature as follows: after washes in
phosphate buffer, followed by quenching of endogenous
peroxidase activity by treatment with 0.1% H2O2, slides
were first incubated with blocking serum (DAKO) for 10
min and then with the affinity-purified antibody for 1
hour. After washes, slides were incubated with bioti-
nylated antibody against rabbit Ig for 20 min followed by
streptavidin-conjugated peroxidase (DAKO LSABR2 kit).
AEC was used as chromogen, according to the supplier's
recommendations for the DAKO LSAB2 kit (Dakocytoma-
tion, Glosturp, Denmark). The tissue sections were then
counterstained with haematoxylin and coverslipped using
Aquatex mounting solution (Merck, Darmstadt, Ger-
many). IHC staining was assessed by two pathologists
(OR, LX) and classified into two categories: negative versus
positive IHC staining. Each IHC staining was obtained
and analyzed twice.
RT-PCR analysis
RT-PCR was used to validate expression data on some of
the samples included in the TMA. The primers and PCR
Table 2: Antibodies and antigen retrieval procedures used for IHC
Protein Origin Clone Dilution Antigen Retrieval
FGFR1 SantaCruz C15 1/200 Demask (DAKO)
MART1 DAKO A103 1/2 Demask (DAKO)
TACC1 Upstate Biotechn. 07–229 1/500 Demask (DAKO)
WT1 Oncogene WLM04 1/100 Citrate (DAKO)
PSA DAKO N1517 rtu* *
*rtu: ready-to-use solution.
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amplification conditions for each tested gene are listed in
Tables 3 and 4. Total RNA was extracted from 17 frozen
tissue samples obtained from the prostatectomy speci-
mens included in the TMA study. RNA extraction was
done by standard protocols [13]. One μg of total RNA was
reverse-transcribed at 42°C for 45 min, in a final volume
of 20 μl containing: 1× reverse transcriptase buffer (Invit-
rogen Corp, Carlsbad, CA), 5 mmol/l MgCl2 (Invitrogen),
1 mmol/l dXTP (Invitrogen), 10 mmol/l dithiorthreitol
(Invitrogen), 5 μmol/l random hexamers (Roche Diag-
nostics, Meylan, France), 20 U RNAse inhibitor (Promega
Biosciences, Madison, WI), 200 U superscript reverse tran-
scriptase (Invitrogen). Reverse transcriptase was inacti-
vated by heating (99°C for 3 min) and cooling (4°C for 5
min). A 4 μl aliquot of this reverse transcription solution
was used for PCR using 50 pmol of each specific primer,
10 mmol dNTP (Invitrogen), 1.5 mmol/l MgCl2 (Invitro-
gen), and 10 × PCR buffer (Invitrogen) in a total volume
of 50 μl (see Table 2 for PCR amplification conditions).
Next to the last PCR cycle, a final extension reaction was
performed (72°C for 7 min). The integrity and amount of
RNA available for preparation of all the cDNAs were
assessed by amplification of the actin gene. Each PCR
reaction included a negative control with H2O instead of
cDNA, a positive control for each cDNA studied (cDNA
from PC3 cell line, and LnCaP cell line for WT1 and
TACC1 respectively, and a human metastatic melanoma
sample for MART1), and a negative control of reverse tran-
scription reaction. The cDNA amplification products were
separated by electrophoresis on 1% agarose gel and
stained by ethidium bromide staining. The cDNA was
then classified as either not amplified (-), or weakly
amplified (+), or strongly amplified (++).
Results
Overexpression of FGFR1, MART1, TACC1, and WT1 
mRNAs in tumor progression in the LuCaP 23.1 carcinoma 
model
The respective expression levels of 945 genes in primary,
HS, and HR stages of LuCaP 23.1 xenograft prostate carci-
noma were compared. They are shown in Figure 1. A gene
was considered as differentially expressed when the ratio
between its median mRNA level in the primary LuCaP
tumor sample and its mRNA level in the HR/HS tumor
sample was more than 2-fold. This threshold was defined
according to our previous reproducibility experiments
[18]. Comparison between primary and HR stages
showed that 27 genes were differentially expressed (Table
5). FGFR1, TACC1 and WT1 were overexpressed in HR
LuCaP 23.1 carcinoma cells (Figure 1A). Comparison
between primary and HS stages showed overexpression of
9 genes (Table 5), including MART1, in HS carcinoma
cells (Figure 1B). Although most genes were expressed at
the same level in HS and HR stages, FGFR1 was clearly
overexpressed in HR stage (Figure 1C).
FGFR1, TACC1 and WT1 proteins display high levels of 
expression in advanced stages of human prostate 
carcinoma
We then assessed the expression of four candidate pro-
teins – FGFR1, MART1, TACC1 and WT1 – in human pros-
tate carcinoma samples by IHC. This choice was
supported by the availability of a corresponding antibody
performing well on paraffin-embedded sections. To this
purpose, we constructed a TMA that included 85 prostate
carcinoma samples from 85 patients and 11 benign pros-
tate tissue samples issued from 11 of these 85 patients.
Results are shown in Table 6 and Figure 2. FGFR1, MART1,
and TACC1 IHC staining was cytoplasmic, while WT1
IHC staining was both nuclear and cytoplasmic (Figure
2). Benign prostate tissue expressed FGFR1 and WT1 less
frequently than carcinoma samples. Among the 86
tumors, pT3 carcinoma samples expressed FGFR1 and
WT1 proteins more frequently than pT2 samples. MART1
was expressed mainly in pT2 carcinomas. MART1 IHC
expression was specific to malignant cells. The high
expression of FGFR1, WT1 in pT3 tumors and MART1 in
pT2 tumors was statistically significant using a chi2 test
(Table 6).
Table 3: Primers used for mRNA amplification by RT-PCR.
TACC1 F: AAATACGAAGAGACCCGGC
R: TGTCCAGTTTCTCTTCTGCG
WT1 F: ATGAGGATCCCATGGGCCAGCA
R: CCTGGGACACTGAACGGTCCCCGA
MART1 F: TGACCCTACAAGATGCCAAG
R: TCAGCATGTCTCAGGTGTCT
Actin F: AGCAAGAGAGGCATCCTGACC
R: CTTCATGATGGAGTTGAAGGTAG
DNA sequences are listed in a 5'→3' orientation (F and R are the forward and reverse DNA strands, respectively).
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MART1, TACC1, and WT1 mRNA levels in human prostate 
samples correlate with IHC findings
We used RT-PCR to assess whether MART1, TACC1, and
WT1 mRNA levels were correlated with IHC expression
levels in 2 benign and 16 malignant prostate samples.
Because the correlation between FGFR1 transcriptional
and post-transcriptional expression has been extensively
discussed in the literature (19), we did not assess FGFR1
mRNA levels in our samples. Results are shown in Figure
3.
MART1 mRNA was weakly expressed in only 1/6 pT2 car-
cinoma, without any expression in pT3 carcinoma or HR
(N1 and/or M1) samples (Figure 3). TACC1 mRNA
expression was stronger in pT2 and pT3 carcinomas than
in benign prostate tissue samples (Figure 3). Furthermore,
TACC1 mRNA expression was strong in HR stage carci-
Table 5: 27 and 9 genes differentially expressed between primary and HR, and between primary and HS LuCaP 23.1 xenografts.
HR vs LUCAP 23.1 Description
FGFR1 Fibroblast growth factor receptor 1
KRT19 Cytokeratin 19
CDK4 Cyclin-dependent kinase 4
AMFR Autocrine motility factor receptor
VEGFR1 Vegf receptor 1/FLT1
ITGA3 Integrin alpha 3/CD49C
MUC1 Polymorphic epithelial mucin
GRB7 GRB7 adaptor
RELA NFKb, p65 subunit
BCL3 BCL3 protein
SRF Serum response factor
MAX MAX transcription regulator
NEO1 Neogenin homolog 1
ITGB5 Integrin beta 5
RXRA Retinoic X receptor alpha
IGFBP4 Insulin-like growth factor binding protein
CASP9 Caspase 9
CREBBP CREB binding protein
MMP15 Membrane-type matrix metalloproteinase 2
SMAD9 MAD homolog 9
BAK Apoptosis regulator bak
MMP9 92 kDa gelatinase, matrix metalloproteinase-9
GATA1 GATA-binding protein 1
MRP5 ATP-binding cassette, sub-family C, member 5
PPP2R2C PP2A BR gamma
EPOR Erythropoietin receptor
FZD5 Frizzled 5, WNT pathway
HS vs LuCaP 23.1
MART1 Melan-a protein
CSTB Cystatin b
NR1H3 Nuclear receptor liver X receptor
VINC Vinculin
STMN1 Stathmin, phosphoprotein p19
STAT1 signal transducer and activator of transcription 1
CBLB Cas-Br-M ectropic retroviral transforming sequence b
WNT2 WNT factor 2
CDH12 Cadherin 12
Table 4: PCR conditions for RT-PCR amplification
GENE N° of cycles Denaturation Annealing Extension
WT1 35 94°C/30 sec 64°C/30 sec 72°C/30 sec
MART1 30 94°C/1 min 60°C/1 min 72°C/2 min
TACC1 30 94°C/1 min 55°C/1 min 72°C/2 min
ACTIN 25 94°C/30 sec 55°C/30 sec 72°C/30 sec
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noma samples (Figure 3). A WT1 mRNA variant (706 bp)
was expressed in 2 of 6 pT2 carcinoma samples, while the
major WT1 mRNA was strongly expressed in pT3 and HR
(N1 and/or M1) carcinoma samples.
Table 6: Expression of FGFR1, MART1, TACC1 and WT1 proteins in human prostate cancer.
Factors benign pT2 pT3 p-value
No. of patients (%)
Age, years 1
<=50 0 0 0
>50 11 39 46
Gleason 0,057
5 0 3 1
6 0 7 4
7 0 25 28
8 0 3 10
9 0 0 4
FGFR1 status 0.001
negative 9 27 17
positive 2 12 29
MART1 status 0.029
negative 11 30 43
positive 0 9 3
TACC1 status 0.756
negative 3 13 12
positive 8 26 34
WT1 status 0.008
negative 9 24 17
positive 2 15 29
Gene expression profiling of initial, HS, and HR stages of LuCaP 23.1 xenograft model of prostate carcinoma illustrated by scat-ter plotsFigur  1
Gene expression profiling of initial, HS, and HR stages of LuCaP 23.1 xenograft model of prostate carcinoma 
illustrated by scatter plots. In each scatter plot, each point is a gene. A: Comparison of gene expression levels between ini-
tial (vertical axis) and HR (horizontal axis) stage carcinomas. FGFR1, WT1, and TACC1 are overexpressed in HR stage. B: Com-
parison of gene expression levels between initial (vertical axis) and HS (horizontal axis) stage carcinomas. MART1 is 
overexpressed in HS stage. C: Comparison of gene expression levels between HS (vertical axis) and HR (horizontal axis) stage 
carcinomas. As shown in A, FGFR1 is overexpressed in HR stage.
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Discussion
Using three methods of analysis (DNA microarrays, TMA,
and RT-PCR), we have shown that FGFR1, TACC1 and
WT1 have much higher levels of expression in human
prostate carcinoma than in benign prostate tissue sam-
ples, at both mRNA and protein levels. We have also
found that FGFR1 and WT1 mRNA are preferentially
expressed in pT3 and/or N1/M1 carcinoma samples, and
that MART1 expression is correlated with HS stage LuCaP
23.1 carcinoma and pT2 prostate carcinoma.
High-throughput screening techniques provide opportu-
nities to identify new diagnostic or prognostic markers
and innovative therapeutic targets in the whole field of
oncology. TMA is a powerful tool to validate DNA micro-
arrays data and extend the scope of gene expression profil-
ing to the post-transcriptional level. Several previous
studies [17,20,22,23] have emphasized how TMAs are
useful to validate the use of candidate prostate carcinoma
markers in routine (IHC) conditions [21].
Potential new markers for prostate cancer progression
We found that expression of FGFR1, WT1, and, to a lesser
extent, TACC1 protein is upregulated in advanced stages
(pT3 and/or N1/M1) of prostate cancer, whereas MART1
is mainly expressed in localized (pT2) stage prostate can-
cer. In the same way, we observed that the corresponding
mRNAs – FGFR1, TACC1, and WT1 on the one hand, and
Immunohistochemistry of FGFR1, TACC1, WT1, and MART1 protein expression in human prostate tissue samples deposited in tissue microarrayFigure 2
Immunohistochemistry of FGFR1, TACC1, WT1, and MART1 protein expression in human prostate tissue 
samples deposited in tissue microarray. A: FGFR1, MART1, and TACC1 IHC stainings are cytoplasmic, while WT1 stain-
ing is both nuclear and cytoplasmic in tumor cells. B: FGFR1, MART1, TACC1, and WT1, expression is more frequent in pros-
tate carcinoma than in benign tissue samples. PSA is used as a positive control, which reacts with prostate secretory and ductal 
epithelium in normal and neoplastic tissue (demonstration of a neoplasm being of prostatic origin). In the table are indicated 
the percentages of positive samples with emphasis on a particular stage (in parenthesis).
TACC1
MART1
FGFR1
PSA/control
WT1 nuclear staining WT1 cytoplasmic staining
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MART1 on the other hand – are overexpressed in HR and
HS stage LuCaP 23.1 prostate carcinoma, respectively.
FGFR1 codes for a tyrosine kinase receptor for members of
the FGF family of growth factors. It is a potential onco-
gene, amplified in breast cancers and rearranged in
hematopoietic diseases. The case of FGFR1 in prostate
cancer is rather clear and our results are in perfect agree-
ment with previous data. Expression of FGFR1 is associ-
ated with increased proliferation and aggressive behavior
of prostate cancer [24,25].
The MelanA/MART1 gene encodes a tyrosinase that is a
marker of melanocytic differentiation [26]. It can be rec-
ognized by cytotoxic T cells [28] and has been considered
as a target for immunotherapy [28]. A previous study has
shown that the protein is expressed in lymph nodes from
breast cancer patients [27]. Our results showed mRNA
overexpression in HS stage LuCaP 23.1 model and IHC
expression of MART1 in about 20% of prostate carcino-
mas, mainly pT2 stages. MART1 expression was strictly
restricted to carcinoma cells, without any staining in
benign prostate tissue. Therefore, we suggest that MART1
may be a marker of some intermediate, hormone sensitive
stage of prostate carcinoma, and that its transient expres-
sion might be shut down during cancer progression
towards hormone resistant and/or advanced clinical
stages (T3 and/or N+ and/or M+).
RT-PCR assessment of MART1, TACC1, and WT1 mRNA expression in benign and neoplastic human prostate carcinoma sam-plesFigure 3
RT-PCR assessment of MART1, TACC1, and WT1 mRNA expression in benign and neoplastic human prostate 
carcinoma samples. - Lanes 1 and 2: negative control (with H2O instead of cDNA), a positive control for each cDNA stud-
ied (cDNA from PC3 cell line and from LNCAP cell line for WT1 and TACC1 respectively, and a human metastatic melanoma 
sample for MART1. - Lanes 3 and 4: n°1 paired benign and malignant (pT2) tissue samples. - Lanes 5 and 6: n°2 paired benign 
and malignant (pT2) tissue samples. - Lanes 7–10: distinct pT2 carcinoma samples. - Lanes 11–15: distinct pT3 carcinoma sam-
ples (13 and 15 are M+ carcinomas). - Lanes 16–20: distinct HR carcinomas samples. 1st line: WT1 mRNA is detected as a 706 
bp PCR product (variant) in 2/6 pT2 carcinoma samples, and as a 851 bp product (wild-type isoform) in 1/2 N1/M1 and 5/5 HR 
carcinoma samples. No WT1 mRNA is present in benign prostate tissue samples. 2nd line: MART1 mRNA is expressed in only 1/
6 pT2 carcinoma sample, but neither in any advanced (pT3 and/or N1/M1) stage nor HR carcinoma samples. 3rd line: TACC1 
mRNA is more strongly expressed in both pT2 and pT3 carcinoma than in benign tissue samples. TACC1 mRNA is also 
expressed in 3/5 HR samples. 4th line: α-actin mRNA amplification is used as a quality control for mRNA extraction and RT-
PCR reaction.
652bp
349bp
207bp
706bp
851bp
ACTIN
MART1
TACC1
WT1
1 2 3 4 5 20191817161514131211109876
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TACC1 belongs to the TACC/taxins (Transforming Acidic
Coiled-Coil) protein family. Taxins are centrosome and
spindle-associated proteins involved in cell division [29].
Mammalian Taxins are probably involved in oncogenesis
in different ways [29,30]. TACC1 maps to 8p11, a region
that is amplified and rearranged in many malignancies
[29-31]. We observed upregulation of TACC1 expression
in prostate carcinoma. This is in agreement with previous
reports focusing on other tumors [32]. Since we found
TACC1 underexpressed in the majority of breast carci-
noma [34], TACC1 role remains to be determined. As pre-
viously suggested, TACC1 might be involved in multiple
complexes that may be deregulated in malignant condi-
tions [33].
The WT1 (Wilms tumor 1) gene encodes a zinc finger
transcription factor that modulates the expression of sev-
eral genes encoding growth factors and receptors (epider-
mal growth factor receptor [35], insulin-like growth factor
II [36], IGF1 receptor [36] and AR [37]. In Wilms tumor,
different point mutations have been described in the WT1
locus, suggesting that WT1 altered protein may be directly
involved in tumor formation. High WT1 expression levels
have been reported in several malignancies [38-41], and
have been linked to a poor prognosis [42]. WT1 expres-
sion and multidrug resistance are associated in some
hematological malignancies, suggesting that WT1 may be
a marker for chemoresistance [43]. We found high expres-
sion levels of WT1 in pT3 stage carcinoma samples, and
expression of wild-type WT1 mRNA in both advanced
stages (≥ pT3) and HR stage LuCaP 23.1 carcinomas.
These results suggest that WT1 expression in prostate car-
cinoma may be associated with progression towards hor-
mone resistance and that WT1 may be considered as a
Schematic representation of the conclusionsFigure 4
Schematic representation of the conclusions. Potential markers of prostate cancer progression, MART1, TACC1 and 
WT1, are shown expressed in representative sections of various stages.
MART 1 TACC1 WT1
Markers of human prostate cancer progression
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potential hormone resistance and prognostic marker in
human prostate carcinoma. These hypotheses are sup-
ported by the strong repression of AR promoter by WT1
[44].
Conclusion
In this study, we identified four candidate genes – FGFR1,
MART1, TACC1 and WT1 – by gene expression profiling
of different stages of prostate carcinoma in an animal
model. The clinical relevance of these candidate genes was
assessed by IHC on TMA of human prostate carcinoma
samples. Our results suggest that each of these four genes
may play a role, or at least reflect a stage of prostate carci-
noma growth/development/progression. MART1 might
be linked to hormone-sensitive growth and localized
tumors, whereas FGFR1, TACC1 and WT1 could be asso-
ciated with hormone-independent growth and advanced
prostate carcinoma (see in Figure 4).
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